Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses mitigating selinexor (Xpovio)-related toxicities in relapsed/refractory multiple myeloma.
Selinexor plus dexamethasone is approved for twice-weekly administration for patients with heavily pretreated multiple myeloma. However, because of the significant gastrointestinal (GI) toxicities associated with selinexor, the agent’s second indication is typically preferred. As such, patients with multiple myeloma who have received at least 1 prior therapy can receive up to 100 mg of oral selinexor in combination with bortezomib (Velcade) once weekly.
Appropriate use of prophylactic agents, such as dexamethasone, 5-hydroxytryptamine receptor antagonists, and aprepitant (Emend), can be given to prevent GI toxicities with selinexor, Hari says. Moreover, with adequate prophylactic treatment, plus potential dose escalation and olanzapine (Zyprexa), selinexor has been shown to be tolerable and highly efficacious for patients with relapsed/refractory multiple myeloma who have limited or no treatment options, concludes Hari.
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab
2 Commerce Drive
Cranbury, NJ 08512